Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)
China · Delayed Price · Currency is CNY 8.55
-0.19 (-2.17%)
Sep 10, 2026, 3:04 PM CST
SHE:002693 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 304.76 | 271.35 | 169.49 | 231.06 | 250.33 | 303.56 |
Other Revenue | 5.04 | 5.41 | 4.71 | 4.87 | 24.42 | 16.74 |
| 309.8 | 276.76 | 174.21 | 235.93 | 274.75 | 320.29 | |
Revenue Growth | 89.55% | 58.87% | -26.16% | -14.13% | -14.22% | 18.87% |
Cost of Revenue | 139.44 | 132.56 | 84.38 | 82.41 | 94.65 | 87.68 |
Gross Profit | 170.36 | 144.2 | 89.83 | 153.52 | 180.1 | 232.61 |
Selling, General & Admin | 98.24 | 110.79 | 143.19 | 175.23 | 202.13 | 264.62 |
Research & Development | 11.23 | 8.09 | 12.89 | 7.96 | 14.59 | 10.62 |
Other Operating Expenses | 11.05 | 7.87 | 5.35 | 6.02 | 7.71 | 7.03 |
Operating Expenses | 120.64 | 126.85 | 161.6 | 190.35 | 224.34 | 282.23 |
Operating Income | 49.71 | 17.35 | -71.77 | -36.83 | -44.24 | -49.62 |
Interest Expense | -9.36 | -9.65 | -9.23 | -9.58 | -11.19 | -9.03 |
Interest & Investment Income | 1.34 | 0.72 | 0.73 | 2.79 | 4.75 | 4.17 |
Currency Exchange Gain (Loss) | -4.86 | -0.93 | 0.36 | 0.12 | 0.01 | -0.1 |
Other Non Operating Income (Expenses) | 0.01 | -0.04 | -0.03 | -0.18 | -0.05 | -0.81 |
EBT Excluding Unusual Items | 36.84 | 7.46 | -79.95 | -43.69 | -50.71 | -55.39 |
Gain (Loss) on Sale of Investments | -0.08 | 0.01 | -10.09 | -39.85 | -0.06 | - |
Gain (Loss) on Sale of Assets | 0.07 | 0.01 | -0.02 | 0.79 | 29.9 | 13.74 |
Asset Writedown | -2.88 | -2.88 | -19.01 | - | -2.1 | - |
Other Unusual Items | 6.38 | 3.56 | 2.9 | 9.78 | 14.09 | 1.29 |
Pretax Income | 40.34 | 8.16 | -106.17 | -72.97 | -8.88 | -40.36 |
Income Tax Expense | -0.54 | -0.76 | 0.1 | -0.99 | -0.38 | 0.45 |
Earnings From Continuing Operations | 40.88 | 8.92 | -106.27 | -71.98 | -8.5 | -40.81 |
Minority Interest in Earnings | 10.26 | 10.12 | 27.96 | 21.23 | 17.51 | 20.48 |
Net Income | 51.14 | 19.04 | -78.3 | -50.74 | 9.01 | -20.33 |
Net Income to Common | 51.14 | 19.04 | -78.3 | -50.74 | 9.01 | -20.33 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 380 | 381 | 412 | 423 | 451 | 407 |
Shares Outstanding (Diluted) | 380 | 381 | 412 | 423 | 451 | 407 |
Shares Change | -7.75% | -7.59% | -2.53% | -6.16% | 10.85% | -0.91% |
EPS (Basic) | 0.13 | 0.05 | -0.19 | -0.12 | 0.02 | -0.05 |
EPS (Diluted) | 0.13 | 0.05 | -0.19 | -0.12 | 0.02 | -0.05 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 34.12 | 17.68 | -65.73 | -37.56 | -7.77 | -8.09 |
Free Cash Flow Per Share | 0.09 | 0.05 | -0.16 | -0.09 | -0.02 | -0.02 |
Gross Margin | 54.99% | 52.10% | 51.56% | 65.07% | 65.55% | 72.62% |
Operating Margin | 16.05% | 6.27% | -41.20% | -15.61% | -16.10% | -15.49% |
Profit Margin | 16.51% | 6.88% | -44.95% | -21.51% | 3.28% | -6.35% |
Free Cash Flow Margin | 11.01% | 6.39% | -37.73% | -15.92% | -2.83% | -2.52% |
EBITDA | 103.11 | 69.98 | -18.3 | 15.84 | 13.3 | 4.71 |
EBITDA Margin | 33.28% | 25.28% | -10.50% | 6.71% | 4.84% | 1.47% |
D&A For EBITDA | 53.4 | 52.62 | 53.48 | 52.67 | 57.54 | 54.33 |
EBIT | 49.71 | 17.35 | -71.77 | -36.83 | -44.24 | -49.62 |
EBIT Margin | 16.05% | 6.27% | -41.20% | -15.61% | -16.10% | -15.49% |
Revenue as Reported | 309.8 | 276.76 | 174.21 | 235.93 | 274.75 | 320.29 |
Advertising Expenses | - | 1.01 | 1.57 | 0.07 | - | - |